Laurus Labs

Laurus Labs is an Indian pharmaceutical company headquartered in Hyderabad. Its focus areas include active pharma ingredients, finished dosage forms, synthesis and biotechnology.[4]

Laurus Labs Limited
TypePublic company
NSE: LAURUSLABS
BSE: 540222
IndustryPharmaceuticals
Founded2005[1]
FoundersDr.Satyanarayana Chava
Headquarters
Hyderabad
,
India
Number of locations
5
Area served
Global
Key people
  • Dr.Satyanarayana Chava (Founder & CEO)[2][3]
ServicesGenerics API, Generics FDF, Synthesis & Biotechnology
Revenue375+ USD in MN - FY20, 280+ USD in MN - H1 FY21
Number of employees
4000 plus
DivisionsAPI, FDF, Synthesis, Ingredients
SubsidiariesLaurus Synthesis, Laurus Bio, Laurus Ingredients, Sriam
Websitelauruslabs.com

Laurus Labs manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA.[5] The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers.

Laurus Labs claims to be the "world's largest third party API supplier for anti-retrovirals".[6] The company also makes Dolutegravir/lamivudine/tenofovir, a medication for HIV/AIDS,[7][8] and hydroxychloroquine tablets, which are used to treat certain types of malaria.[9]

In March 2020, Laurus Labs received US Food and Drug Administration approval to market hydroxychloroquine tablets. The company announced that it would supply hydroxychloroquine for clinical trials of preventive treatment of COVID-19.[10]

References
  1. "Laurus Labs Ltd". Bloomberg. Retrieved 17 April 2020.
  2. "Laurus Labs banking on vertical integration to crack anti-HIV tenders and US formulations mkts". Moneycontrol. Retrieved 17 April 2020.
  3. "Laurus Labs: A hot startup in the pharma sector". Forbes India. Retrieved 17 April 2020.
  4. "Laurus Labs Share Price: Company forays into Lucrative Biotech Space". Zee Business. 2020-11-27. Retrieved 2020-11-27.
  5. Trivedi, Isha. "Laurus Labs strikes gold by moving up the value chain. But there's a steeper climb ahead". The Economic Times. Retrieved 2020-10-19.
  6. "Laurus Labs eyes bigger play in generic formulations segment". Times of India. Retrieved 17 April 2020.
  7. "Laurus Labs gets USFDA nod for HIV drug". Economic Times Health. Retrieved 17 April 2020.
  8. "Laurus Labs is ready to flood the US with cheap HIV drugs". Livemint. Retrieved 17 April 2020.
  9. "Laurus Labs gets USFDA nod for malaria tablets". The Hindu Business Line. Retrieved 17 April 2020.
  10. "Coronavirus: Laurus Labs to supply Hydroxychloroquine for clinical trials in the US". Moneycontrol. Retrieved 17 April 2020.

[1]

  1. "Laurus Labs subsidiary incorporates Laurus Ingredients; stock gains 1%". www.indiainfoline.com. Retrieved 2021-01-20.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.